The natural history of vincristine-induced laryngeal paralysis in children.
OBJECTIVE
To outline the natural history of vincristine-induced laryngeal paralysis (VLP) in children.


METHODS
Retrospective case series and review of reported cases in the English-language literature.


METHODS
Tertiary pediatric center.


METHODS
The study included all children with a confirmed diagnosis of VLP by inspection and with complete clinical information. The sources for patient identification were a prospectively kept database and a review of the English-language literature, conducted on PubMed since 1966, as well as a bibliography search.


METHODS
Charts and literature were reviewed for demographics, primary diagnosis, other diagnoses, and duration and method of treatment. The prevalence of VLP, locally, was also calculated.


RESULTS
Four children (3 boys and 1 girl) were identified in our database over a 5(1/2)-year period, and 10 children (1 girl, 8 boys, and 1 with sex omitted) were described in the English-language literature. Four children had unilateral vocal fold paralysis only, all left-sided. The median age was 2.6 years. Acute lymphoblastic leukemia was the underlying diagnosis in 8 patients. Two patients had Down syndrome, and 1 patient had Charcot-Marie-Tooth disease, type 1. Only 2 patients required tracheotomies, and 1 patient was treated temporarily with bilevel positive-pressure ventilation. The median duration of paralysis was 6.8 weeks. The prevalence of VLP was 1.36%.


CONCLUSIONS
The data suggest that VLP is probably underreported and possibly underdiagnosed. Endoscopic inspection is a must in all patients with airway symptoms who are receiving vincristine therapy. Early recognition of VLP is mandatory, as it is reversible, has a good prognosis, and usually needs only interruption of vincristine therapy and conservative treatment.
Kuruvilla
George
G
Pediatric Otolaryngology Service, Division of Pediatric Surgery, The Stollery Children's Hospital, Edmonton, Alberta, Canada.
Perry
Shirley
S
Wilson
Beverly
B
El-Hakim
Hamdy
H
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D012189:Retrospective Studies; D014750:Vincristine / Q000009:adverse effects*; D014826:Vocal Cord Paralysis / Q000139:chemically induced*
D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine